New Automated Extraction System Produces High Quality RNA-free DNA
By LabMedica International staff writers Posted on 18 Oct 2015 |
A state-of-the-art precipitation-based system completely automates the DNA extraction process from primary tube sampling to final DNA elution into storage tubes.
The AutoGen (Holliston, MA, USA), FlexSTAR+ platform is a system that produces RNA-free DNA in an extremely user-friendly environment.
The FlexSTAR+ system includes protocols for fresh or frozen blood samples of 1 to 2 milliliters, 3 to 5 milliliters, and 6 to 10 milliliters. The instrument can draw samples from a variety of primary tube sizes, running up to 30 samples in a batch. It reads and records barcodes on primary tubes, has an internal barcode scanner to verify sample input and DNA output positions, provides liquid level detection for accurate pipetting, and delivers its final elution in SBS (sterile barrier system)-type storage tubes of the user’s choosing.
FlexSTAR+ features sample tracking and reporting software that verifies work lists from LIM (laboratory information management) input, creates a map of sample and DNA positions, tracks samples through the extraction process, and sends final reports back to LIMs. The software also sends an email or text alert to notify the operator when the run is complete.
The extraction process operates with Qiagen (Venlo, The Netherlands) FlexiGene chemistry. This precipitation-based procedure yields cleaner, longer-stranded DNA than does magnetic bead-based methods. Furthermore, since the Qiagen DNA extraction process begins with the collection of the white cell nuclei pellet, it eliminates RNA contamination that can occur with magnetic bead technology and other technologies that produce total nucleic acid instead of pure genomic DNA.
“Biorepositories, genetic treatment and cancer centers, and specialty diagnostic labs that currently are using Qiagen’s AutoPure solution for DNA extraction will be familiar and comfortable with precipitation technology,” said Bob Sullivan, president and CEO of AutoGen. “FlexSTAR+ is a logical step-up for them. In fact, it is a superior solution for any lab that wants to generate higher quality, higher yield genomic DNA with less work and errors and far less likelihood of RNA contamination, and that stands to benefit from the superior service for which AutoGen is known.”
Related Links:
AutoGen
Qiagen
The AutoGen (Holliston, MA, USA), FlexSTAR+ platform is a system that produces RNA-free DNA in an extremely user-friendly environment.
The FlexSTAR+ system includes protocols for fresh or frozen blood samples of 1 to 2 milliliters, 3 to 5 milliliters, and 6 to 10 milliliters. The instrument can draw samples from a variety of primary tube sizes, running up to 30 samples in a batch. It reads and records barcodes on primary tubes, has an internal barcode scanner to verify sample input and DNA output positions, provides liquid level detection for accurate pipetting, and delivers its final elution in SBS (sterile barrier system)-type storage tubes of the user’s choosing.
FlexSTAR+ features sample tracking and reporting software that verifies work lists from LIM (laboratory information management) input, creates a map of sample and DNA positions, tracks samples through the extraction process, and sends final reports back to LIMs. The software also sends an email or text alert to notify the operator when the run is complete.
The extraction process operates with Qiagen (Venlo, The Netherlands) FlexiGene chemistry. This precipitation-based procedure yields cleaner, longer-stranded DNA than does magnetic bead-based methods. Furthermore, since the Qiagen DNA extraction process begins with the collection of the white cell nuclei pellet, it eliminates RNA contamination that can occur with magnetic bead technology and other technologies that produce total nucleic acid instead of pure genomic DNA.
“Biorepositories, genetic treatment and cancer centers, and specialty diagnostic labs that currently are using Qiagen’s AutoPure solution for DNA extraction will be familiar and comfortable with precipitation technology,” said Bob Sullivan, president and CEO of AutoGen. “FlexSTAR+ is a logical step-up for them. In fact, it is a superior solution for any lab that wants to generate higher quality, higher yield genomic DNA with less work and errors and far less likelihood of RNA contamination, and that stands to benefit from the superior service for which AutoGen is known.”
Related Links:
AutoGen
Qiagen
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples